Corient Private Wealth
PCVX icon

Corient Private Wealth’s Vaxcyte PCVX Stock Holding History

Corient Private Wealth’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
36,894
+33,076
+866% +$1.8M ﹤0.01% 1354
2026
Q1 		$222K Buy
+3,818
New +$207K ﹤0.01% 2495
2025
Q1 		– Sell
-5,404
Closed -$442K – 2406
2024
Q4 		$442K Buy
5,404
+3,160
+141% +$314K ﹤0.01% 1687
2024
Q3 		$256K Buy
+2,244
New +$202K ﹤0.01% 2091

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Corient Private Wealth's PCVX Position: Q2 2026 in Review

Corient Private Wealth increased its Vaxcyte (PCVX) stake by 866% in Q2 2026, buying an estimated $1.8M and bringing the position to 36,894 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1354.

Corient Private Wealth first reported a position in PCVX in Q3 2024 and has held it in 4 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Corient Private Wealth held 36,894 shares of Vaxcyte worth $2.14M as of Q2 2026.
  • Corient Private Wealth bought 33,076 Vaxcyte shares in Q2 2026, an estimated $1.8M.
  • Vaxcyte made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1354 holding.
  • Corient Private Wealth first reported a position in Vaxcyte in Q3 2024 and has held it in 4 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.